Financial Results Nine month period 2019 - Video

Javier López-Belmonte, Vicepresident and CFO of Laboratorios Farmacéuticos ROVI presents the financial results for the first nine months of 2019.


No votes yet
 
Related
ROVI and Moderna Announce Collaboration for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a...
3 min
09/07/2020
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
Operating revenue increased by 23% to 101.0 million euros in the first quarter of 2020, mainly driven by the strength of the specialty...
7 min
13/05/2020